They concluded that mechanistically, melatonin inhibits HIF-1α stabilization and nuclear translocation in prostate cancer cells via inactivation of the SPHK-1 and Akt/GSK-3β, culminating in the demonstrated anti-angiogenic activity. The gene discussed is SPHK1; the disease is prostate cancer.